Description
Seeking men and women whose high-risk, non-muscle invasive bladder cancer has not spread to the muscle for a study comparing the standard Bacillus Calmette-Guerin (BCG) immunotherapy to an investigational chemotherapy drug combination.
Overview
Participants will be randomly assigned to get either the standard Bacillus Calmette-Guerin (BCG) immunotherapy or an experimental chemotherapy combination given through a catheter directly into the bladder. People receiving BCG immunotherapy who show a response will continue to be treated with BCG once a week for three weeks in a row for up to 3 years. People receiving the experimental chemotherapy who show a response will continue to get the chemotherapy monthly for up to 2 years.
What we're hoping for
We are comparing an experimental chemotherapy to the standard Bacillus Calmette-Guerin (BCG) immunotherapy for prevention of the return of cancer in people with high-risk, non-muscle invasive bladder cancer has not spread to the muscle
Additional Information
ClinicalTrials.gov Identifier: NCT05538663